Targanta Therapeutics To Present At 9th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference Therapeutic Workshop

CAMBRIDGE, Mass., Feb. 9 /PRNewswire-FirstCall/ -- Targanta Therapeutics, a privately held biopharmaceutical company developing antibacterial drugs, today announced that Thomas Parr, Ph.D., the Company's Chief Scientific Officer, will participate in a Therapeutic Workshop as part of the BIO CEO Investor Conference to be held from February 12-14 in New York City at the Waldorf Astoria Hotel.

The workshop, entitled "The War On Bugs: Just Say No" will take place on Monday, February 12 at 3:30 PM ET in the hotel's West Foyer and will focus on issues including emerging drug-resistant bacteria, ways to treat them effectively by improving old drugs, and by developing new ones. Dr. Parr will discuss the novel glycopeptide antibiotic, oritavancin, Targanta's lead drug candidate, its mechanisms of action and its activity against antibiotic-resistant pathogens.

About Oritavancin

Oritavancin, Targanta's lead product candidate, is a once-daily, semi- synthetic glycopeptide antibiotic with rapid bactericidal activity against all clinically relevant serious gram-positive infections, including multi- resistant strains. Oritavancin's multiple targets and mechanisms of action work against the development of resistant strains, which is important when treating serious gram-positive infections. To date, over 1,500 individuals have received oritavancin in clinical trials, including two large multicenter Phase III studies to demonstrate oritavancin as an effective and safe therapy for complicated skin and skin structure infections. Targanta expects to file a New Drug Application (NDA) for oritavancin with the U.S. Food and Drug Administration in 2007.

About Targanta Therapeutics

Targanta Therapeutics is a privately held biopharmaceutical company developing and commercializing antibacterial drugs to treat serious infections in the hospital setting. Its pipeline includes an array of antibacterial agents in various stages of development. The company has operations in Cambridge, MA, Indianapolis, IN and Montreal, Canada. For further information about Targanta, visit the company website, www.targanta.com.

CONTACT: Brian Ritchie - Investors, Robert Stanislaro - Media, both ofFinancial Dynamics for Targanta Therapeutics, +1-212-850-5600,targanta@fd.com

Web site: http://www.targanta.com/